Legal entity
All 1 tracked stories fall under one category: regulation. Peter Marks is most often covered alongside Center for Biologics Evaluation and Research (CBER), which appears in 1 of these 1 story. Source depth averages 8 original sources per story, versus 3.1 across the same-window beat baseline.
Last mentioned: Mar 7, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Peter Marks is most often covered alongside Center for Biologics Evaluation and Research (CBER), which appears in 1 of these 1 story. Source depth averages 8 original sources per story, versus 3.1 across the same-window beat baseline. Their average consequence score of 8 runs above the beat's 7.2 for that window. We currently track 1 Legal story that mention Peter Marks, all published on February 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Peter Marks. Shared-story counts are live from our verified record — not editorial picks.
Expedited Pathway Formalized
FDA announces the formal implementation of quicker paths for gene therapy via surrogate endpoints.
START Pilot Launch
FDA initiates a pilot program for Support for clinical Trials Advancing Rare disease Therapeutics.
CBER Reorganization
The Office of Tissues and Advanced Therapies is elevated to a 'Super Office' to handle CGT volume.
Luxturna Approval
FDA approves the first gene therapy for an inherited disease, setting the initial regulatory precedent.
The U.S. Food and Drug Administration has established a streamlined regulatory pathway to expedite the development and review of gene therapies. This initiative focuses on leveraging surrogate endpoints and platform technologies to bring life-altering treatments for rare diseases to market faster.
Peter Marks is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
